Figure 3.

In vivo interactions of BRCA2 with RAD51. (A) Cell lysates (50 μg of total protein; lanes 1 and 2) and mAb B2 (lanes 3 and 4) or anti-IgG (lane 5) immunoprecipitates (from 2.5 mg of total protein) were resolved by 10% SDS/PAGE, and immunoblotted with anti-RAD51. (B) Cell lysates (50 μg of total protein for CAPAN-1, and 25 μg of total protein for MCF7; lanes 1 and 2) and mAb B2 immunoprecipitates (from 4 mg of total protein for CAPAN-1, and 2 mg of total protein for MCF7; lanes 3 and 4) were resolved by 10% SDS/PAGE and immunoblotted with anti-RAD51. (C) 293T cells transfected with pHA-RAD51 or the control HA vector were lysed and immunoprecipitated with anti-HA, mAb B2, or anti-IgG. Lysates (lanes 1 and 2) and immunoprecipitates (lanes 3–5) were separated by 4% SDS/PAGE and immunoblotted with anti-C15, or 10% SDS/PAGE and immunoblotted with anti-HA. Anti-IgG immunoprecipitates from HA-RAD51 transfected cells were used as a specificity control (lane 5).